French biotech startup Osivax secures €8M to develop universal vaccine against…
A biotech startup from France, Osivax announced today that it has secured €8 million of financing through a Series A financing round to fund further progress in the clinical development of its lead flu vaccine candidate and to support strategic corporate growth.